ADTX vs. GLMD, CMND, QLGN, LSDI, DRMA, CWBR, PBLA, PRFX, ATNF, and NBSE
Should you be buying Aditxt stock or one of its competitors? The main competitors of Aditxt include Galmed Pharmaceuticals (GLMD), Clearmind Medicine (CMND), Qualigen Therapeutics (QLGN), Lucy Scientific Discovery (LSDI), Dermata Therapeutics (DRMA), CohBar (CWBR), Panbela Therapeutics (PBLA), PainReform (PRFX), 180 Life Sciences (ATNF), and NeuBase Therapeutics (NBSE). These companies are all part of the "pharmaceutical preparations" industry.
Galmed Pharmaceuticals (NASDAQ:GLMD) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk.
Galmed Pharmaceuticals has a net margin of 0.00% compared to Galmed Pharmaceuticals' net margin of -5,016.31%. Aditxt's return on equity of -53.29% beat Galmed Pharmaceuticals' return on equity.
Galmed Pharmaceuticals has higher earnings, but lower revenue than Aditxt.
76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 1.2% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Galmed Pharmaceuticals received 438 more outperform votes than Aditxt when rated by MarketBeat users. Likewise, 65.29% of users gave Galmed Pharmaceuticals an outperform vote while only 44.44% of users gave Aditxt an outperform vote.
Galmed Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.
Aditxt has a consensus target price of $61.00, indicating a potential upside of 3,077.08%. Given Galmed Pharmaceuticals' higher probable upside, analysts plainly believe Aditxt is more favorable than Galmed Pharmaceuticals.
In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Aditxt. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 1 mentions for Aditxt. Galmed Pharmaceuticals' average media sentiment score of 1.87 beat Aditxt's score of 0.72 indicating that Aditxt is being referred to more favorably in the news media.
Summary
Galmed Pharmaceuticals beats Aditxt on 9 of the 13 factors compared between the two stocks.
Get Aditxt News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
